Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)



Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor Inc. (NASDAQ:XNCR) stock performance was -1.58% in last session and finished the day at $13.68. Traded volume was 99,904.00 shares in the last session and the average volume of the stock remained 111,589.00 shares. Xencor Inc. (NASDAQ:XNCR) insider ownership is 30.60%.

Albany Molecular Research Inc. (NASDAQ:AMRI) move into Buffalo remains delayed, but a state official is optimistic that the drug-development company will be up and running by April in temporary space on the Buffalo Niagara Medical Campus. Albany Molecular Research, Inc. (NASDAQ:AMRI) rose 5.85% to $17.18 yesterday on volume of 1.69 million shares. The intra-day range of the stock was $16.35 – $18.18. Albany Molecular Research, Inc. (NASDAQ:AMRI) has a market capitalization of 551.24 million.

Oncothyreon (NASDAQ:ONTY) issued its quarterly earnings data on Thursday. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.10) by $0.01, ARN reports. Oncothyreon Inc. (USA) (NASDAQ:ONTY)’s stock on March 13, 2014 reported a higher of 4.57% to the closing price of $3.89. Its fifty two weeks range is $1.55 – $4.08. The total market capitalization recorded 233.25 million. The overall volume in the last trading session was 2.09 million shares. In its share capital, Oncothyreon Inc. (USA) (NASDAQ:ONTY) has 59.96 million outstanding shares.

Oxigene Inc. (NASDAQ:OXGN) said on Tuesday that its experimental drug Zybrestat combined with Roche’s big selling cancer drug Avastin significantly slowed progression of recurrent ovarian cancer better than Avastin alone in a midstage clinical trial. On Thursday, shares of OXiGENE Inc. (NASDAQ:OXGN) dropped -2.56% to close the day at $4.18. Company return on investment (ROI) is -177.80% and its monthly performance is recorded as 51.45%. OXiGENE Inc. (NASDAQ:OXGN) quarterly revenue growth is 63.92%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone